IDiyas

For the Inventor, By the Inventor

Barcelona, Spain

Paul Robert Eastwood

USPTO Granted Patents = 12 

 

Average Co-Inventor Count = 4.3

ph-index = 4

Forward Citations = 51(Granted Patents)


Location History:

  • Rubi, ES (2012 - 2014)
  • Barcelona, ES (2008 - 2015)

Company Filing History:

goldMedal6 out of 57 
 
Almirall, S.a.
 patents
silverMedal4 out of 207 
 
Aventis Pharmaceuticals Inc.
 patents
bronzeMedal2 out of 21 
 
Laboratorios Almirall, S.a.
 patents

Years Active: 2008-2015

Loading Chart...
Loading Chart...
12 patents (USPTO):Explore Patents
1. 9206183 - Substituted pyrazolo[1,5-a]pyridines as JAK inhibitors (2015-12-08),
2. 9034311 - Pyridin-2(1 H)-one derivatives as JAK inhibitors (2015-05-19),
3. 8772288 - Substituted spiro[cycloalkyl-1,3'-indo]-2′(1′H)-one derivatives and their use as P38 mitogen-activated kinase inhibitors (2014-07-08),
4. 8450341 - Substituted indolin-2-one derivatives and their use as P38 mitogen-activated kinase inhibitors (2013-05-28),
5. 8334294 - 4,8-diphenyl-polyazanaphthalene derivatives (2012-12-18),
6. 8258122 - 3-([1,2,4]triazolo[4,3-a]pyridin-7-yl)benzamide derivatives (2012-09-04),
7. 8173682 - Substituted pyridones as inhibitors of poly(ADP-ribose) polymerase (PARP) (2012-05-08),
8. 8008491 - Substituted AZA-indoles as inhibitors of poly(ADP-ribose) polymerase (PARP) (2011-08-30),
9. 7855202 - [object Object] (2010-12-21),
10. 7790728 - Pyrazine derivatives useful as adenosine receptor antagonists (2010-09-07),
11. 7625889 - [object Object] (2009-12-01),
12. 7405300 - Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP) (2008-07-29),

Title: Inventor Spotlight: Paul Robert Eastwood

Introduction: Paul Robert Eastwood is an accomplished inventor based in Barcelona, Spain, known for his significant contributions in the field of pharmacology. With a total of 12 patents to his name, Eastwood has focused primarily on developing innovative therapeutic agents targeting Janus Kinases (JAK).

Latest Patents: Among Eastwood's most notable patents are the "Substituted pyrazolo[1,5-a]pyridines as JAK inhibitors" and "Pyridin-2(1H)-one derivatives as JAK inhibitors." The former patent reveals new pyrazole derivatives characterized by a specific chemical structure, detailing their preparation processes and applications in therapy as JAK inhibitors. Similarly, the latter patent describes novel pyridin-2(1H)-one derivatives, including their preparation and use in pharmaceutical compositions aimed at inhibiting Janus Kinases.

Career Highlights: Paul Eastwood has had a distinguished career, working with prominent companies such as Almirall, S.A. and Aventis Pharmaceuticals Inc., where he contributed to the advancement of pharmaceutical research and innovation. His work has greatly influenced therapeutic approaches in managing diseases associated with JAK pathways.

Collaborations: Throughout his career, Eastwood has collaborated with notable professionals in the field, including Jacob Gonzalez Rodriguez and Bernat Vidal Juan. These partnerships have fostered an environment of innovation and have played a crucial role in the development of his patents.

Conclusion: Paul Robert Eastwood stands out as a significant figure in the realm of pharmacological innovations. His commitment to researching and developing JAK inhibitors is paving the way for new therapies, further solidifying his status as a leading inventor in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…